% | $
Quotes you view appear here for quick access.

MSCI Inc. Message Board

palosparkflash 2 posts  |  Last Activity: Jul 11, 2016 10:33 AM Member since: Dec 27, 2001
  • palosparkflash by palosparkflash Jul 11, 2016 10:33 AM Flag

    Its the 10-K that has people running for the exits.

    *BZ NOTE: Most Recent 10-K Shows Risks: 'USPS regulations or fee assessments may cause disruptions or discontinuance of our business'

  • - RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection;
    - RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; and
    - RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 to treat nonalcoholic steatohepatitis in patients with type 2 diabetes/pre-diabetes.

    The company has strategic alliances with:
    - GSK to discover and develop microRNA therapeutics for immuno-inflammatory diseases;
    - Sanofi to discover and develop microRNA therapeutics for fibrotic diseases;
    - AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and
    - Biogen Inc. to evaluate the use of microRNA signatures as a biomarker for human patients with various sclerosis.

    Sentiment: Buy

86.40-0.37(-0.43%)Sep 23 4:02 PMEDT